Percutaneous ablation for small renal masses

Current guidelines recommend partial nephrectomy as the preferred treatment option for small renal masses. Percutaneous ablation, such as radiofrequency ablation and cryoablation, are mainly considered for patients who are not suitable for surgery or who have other conditions (co-morbidities) that make them unfit for surgery. There is currently a lack of evidence comparing partial nephrectomy […]

read more

Long term survival after radiofrequency ablation for kidney cancer

A study published in the Journal of Vascular and Interventional Radiology looked at the long-term survival benefits from radiofrequency ablation (RFA) in patients with localised renal cell carcinoma (RCC). The outcomes of 100 patients with localised RCC (kidney cancer that has not spread) were looked at retrospectively. All patients had percutaneous radiofrequency ablation and were […]

read more

Radiofrequency ablation and systemic treatment for kidney cancer lung metastases

A recent study published in BMC Cancer reports on the safety and efficacy of radiofrequency ablation (RFA) for local treatment of renal cell carcinoma (RCC) lung metastases in combination with systemic treatments. The researchers treated 100 lung metastases in 53 patients with RFA. Median follow-up time was 61 months and 5-year overall survival was 62%. Median […]

read more

Outcomes following partial nephrectomy and percutaneous ablation for small renal masses

A study published in European Urology presents retrospective data from the Mayo Clinic in America regarding their experience with partial nephrectomy, percutaneous radiofrequency ablation (RFA) and percutaneous cryoablation for small renal masses (less than 4 cm, stage cT1). Long-term follow-up data from 1798 patients with primary cT1N0M0 renal tumours were treated with partial nephrectomy, RFA […]

read more

Percutaneous ablation for localised kidney tumours

A recent study reported in European Urology by investigators at the Mayo Clinic in Rochester, Minnesota, USA compared partial nephrectomy with percutaneous ablation (radiofrequency ablation or cryoablation) in the treatment of 1422 patients with localised renal tumours, stage cT1. Patients were followed for at least 6 years. There were no significant differences in local recurrence, […]

read more

Kidney cancer experts talk about the latest advances in treatments

The following interviews with kidney cancer experts discuss the latest advances in the treatment of renal cell carcinoma (RCC) and renal masses: No OS signal in axitinib + avelumab combination therapy – Dr Toni Choueiri, Dana Faber Cancer Institute, Boston, USA Treating renal masses with minimal invasive ablative technique – Dr Alessandro Volpe, Maggiore Della […]

read more

Ablation versus surgery for early stage kidney tumours

A recent paper, published in Annals of Internal Medicine, suggests that percutaneous ablation using heat or cold may result in similar outcomes to those of radical nephrectomy in preselected older patients with early stage renal cell carcinoma (T1a RCC). Percutaneous ablation also results in less long-term renal insufficiency and fewer surgical complications. When compared to […]

read more

Von Hippel-Lindau (VHL) disease and the risk for kidney cancer

Von Hippel-Lindau (VHL) disease is caused by a change (mutation) in a tumour suppressor gene, called the VHL gene. When the VHL gene is mutated, this can lead to uncontrolled cell growth and the development of cancer. Lack of VHL protein caused by the mutation can also increase the growth of new blood vessels (angiogenesis), causing the […]

read more
Showing all 8 results
  TOP